Targeting DUSP5 suppresses malignant phenotypes of BRAF-mutant thyroid cancer cells and improves their response to sorafenib

ConclusionsOur data demonstrate an oncogenic role ofDUSP5 in BRAF-mutant thyroid cancer cells, and combined analysis of its expression andBRAFV600E mutation can accurately diagnose thyroid cancer. In addition, inhibition of DUSP5 improves the response of BRAF-mutant thyroid cancer cells to sorafenib.

http://rd.springer.com/10.1007/s12020-024-03801-8

Source: Endocrine - April 2, 2024 Category: Endocrinology Source Type: research